13 Undervalued Dividend Aristocrats to Buy Now

Page 9 of 12

4. Becton, Dickinson and Company (NYSE:BDX)

Forward P/E Ratio as of March 9: 12.97

Becton, Dickinson and Company (NYSE:BDX) is one of the world’s largest pure-play medical technology companies in the world. BD drives innovation across medical essentials, connected care, biopharma systems, and interventional.

Becton, Dickinson and Company (NYSE:BDX) announced on March 2 that it had received 510(k) clearance from the FDA for its Surgiphor™ 1000mL irrigation system. The device is designed for powered lavage procedures and provides a standardized, OR-ready solution to help loosen and remove debris and microorganisms from wounds. Moreover, the system comes ready-to-use and completely sterile. This eliminates the need for hospital staff to mix solutions by hand and saves valuable time.

Becton, Dickinson and Company (NYSE:BDX)’s Surgiphor™ portfolio now offers both manual and powered irrigation options, giving doctors the flexibility to match the needs of their workflow and patient population.

Rian Seger, worldwide president of the Surgery business at Becton, Dickinson and Company (NYSE:BDX), stated:

“This FDA clearance reinforces BD’s position as the global leader in surgical irrigation innovation. Surgiphor™ 1000mL is a unique solution that provides the consistency and safety surgical teams expect from BD, allowing them to focus on what matters most: providing better, safer care for their patients.”

Becton, Dickinson and Company (NYSE:BDX) is targeting its adjusted EPS to be in the range of $12.35 to $12.65 for FY 2026, reflecting a 6% growth at the midpoint compared to last year.

Page 9 of 12